Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.

Opinion

Case: 24-1564 Document: 28 Page: 1 Filed: 08/20/2024

NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________

REGENERON PHARMACEUTICALS, INC., Appellant

v.

MYLAN PHARMACEUTICALS INC., CELLTRION, INC., SAMSUNG BIOEPIS CO., LTD., Appellees ______________________

2024-1564, 2024-1567 ______________________

Appeals from the United States Patent and Trademark Office, Patent Trial and Appeal Board in Nos. IPR2022- 01225, IPR2022-01226, IPR2023-00532, IPR2023-00533, and IPR2023-00566. ______________________

ON MOTION ______________________

ORDER Upon consideration of Regeneron Pharmaceuticals, Inc.’s unopposed motion to voluntarily dismiss the above- captioned appeals pursuant to Federal Rule of Appellate Procedure 42, Case: 24-1564 Document: 28 Page: 2 Filed: 08/20/2024

IT IS ORDERED THAT: (1) The motion is granted, and the appeals are dis- missed. (2) Each party shall bear its own costs for each appeal. FOR THE COURT

August 20, 2024 Date

ISSUED AS A MANDATE: August 20, 2024